All CIRM Grants

Search Filters »

Institution Researcher name Grant Type Grant Title Award Value
University of California, Los Angeles Dr. Jerome A. Zack Ph.D. Late Stage Preclinical Projects Clinical Translation of Autologous Regenerative Pluripotent Stem Cell Therapy for Blindness $6,000,000
Kenai Therapeutics Howard J Federoff Late Stage Preclinical Projects Allogeneic iPSC derived Dopaminergic Drug Product for Parkinson’s disease $4,000,000
Rampart Bioscience Jeffrey Bartlett Late Stage Preclinical Projects Ex vivo Engineering of Autologous Hematopoietic Stem Cells for the Treatment of Hypophosphatasia $3,999,980
Nammi Therapeutics, Inc. Dr. David R Stover Late Stage Preclinical Projects IND-Enabling activities for the masked immunocytokine, QXL138AM $3,999,113
Calidi Biotherapeutics, Inc. 8587949607 Boris Minev Late Stage Preclinical Projects Allogeneic mesenchymal stem cells loaded with oncolytic virus for cancer treatment $3,111,467
Ossium Health, Inc. Dr. Brian Johnstone Late Stage Preclinical Projects Development of OSSM-007, cryopreserved interferon-gamma primed allogeneic MSCs, for treatment of steroid refractory acute graft versus host disease $3,457,858
University of California, Davis Dr. Joseph S Anderson Late Stage Preclinical Projects Hematopoetic stem cell gene therapy for the treatment of Tay-Sachs disease $4,048,253
Stanford University Natalia Gomez-Ospina Late Stage Preclinical Projects Genome Editing of Autologous Hematopoietic Stem Cells to Treat Severe Mucopolysaccharidosis type 1 (Hurler Syndrome) $5,444,353
University of California, San Francisco Dr. Karin Lindgren Gaensler Late Stage Preclinical Projects Development of TriLeukeVax, an Engineered Autologous Leukemia Vaccine for Stimulating Cytolytic Immune Responses to Residual Leukemic Stem Cells $6,000,000
ImmunoVec Dr. Ryan L. Wong Late Stage Preclinical Projects Hematopoietic Stem Cell Gene Therapy for XCGD $3,999,959
University of California, Los Angeles Dr. Antoni Ribas MD/PhD Late Stage Preclinical Projects Skin regeneration and wound healing with a topical BRAF inhibitor $5,005,126
University of Southern California Frank Petrigliano Late Stage Preclinical Projects Plurocart: a novel stem cell-based implant for articular cartilage restoration $5,999,782
University of California, San Diego Thomas J Kipps Late Stage Preclinical Projects Late Stage Pre-Clinical Development of a Cirmtuzumab Based CAR T-cell for the Treatment of ROR1+ Hematological Malignancies $2,160,000
Stanford University Dr. Rosa Bacchetta Late Stage Preclinical Projects IND-enabling activities for a Phase 1 Study of Autologous CD4LVFOXP3 T Cells in Subjects with IPEX Syndrome $5,002,496
University of California, San Francisco Mark C. Walters M.D. Late Stage Preclinical Projects Curing Sickle cell Disease with CRISPR-Cas9 genome editing $2,242,805
University of California, Davis Dr. Diana L. Farmer Late Stage Preclinical Projects Placental Mesenchymal Stem Cell Augmentation of Fetal Myelomeningocele Repair $5,615,207
Ankasa Regenerative Therapeutics, Inc. Ying Zhu Late Stage Preclinical Projects IND-enabling development of ART352-L, an endogenous stem cell reactivation therapy to enhance bone healing in the elderly $3,987,693
City of Hope, Beckman Research Institute Xiuli Wang Late Stage Preclinical Projects CMV-specific T cells expressing anti-HIV CAR and CMV vaccine boost as immunotherapy for HIV/AIDS $3,812,797
University of California, San Francisco Dr. Krystof Bankiewicz Late Stage Preclinical Projects MRI Guided Delivery of Neural Progenitor Cells Secreting GDNF for the Treatment of Parkinson’s disease $5,757,078
Poseida Therapeutics, Inc. Devon J Shedlock Late Stage Preclinical Projects Late-Stage Preclinical Study of CAR-T Memory Stem Cells Targeting PSMA (P-PSMA-101) for the Treatment of Castrate-Resistant Metastatic Prostate Cancer $3,992,090
City of Hope, Beckman Research Institute Dr. Angelo Manuel Almeida Cardoso Ph.D., MD Late Stage Preclinical Projects Ex Vivo Gene Engineering of Blood Stem Cells for Enhanced Chemotherapy Efficacy in Glioblastoma Patients $3,684,259
University of California, Irvine Dr. Leslie M Thompson Late Stage Preclinical Projects An hESC-derived hNSC Therapeutic for Huntington’s Disease $5,635,393
Fate Therapeutics, Inc. Dr Bob Valamehr Late Stage Preclinical Projects IND enabling development of FT516: A Natural Killer Cell Immunotherapy for Cancer Derived from a Human Inducible Pluripotent Stem Cell $4,000,000
Stanford University Dr. Matthew H Porteus Late Stage Preclinical Projects Genome Editing of Autologous Hematopoietic Stem Cells to Treat Sickle Cell Disease $4,849,363
Cellerant Therapeutics, Inc. Swapna Panuganti Late Stage Preclinical Projects Development of CLT030-ADC, a Leukemic Stem Cell Targeting Antibody-Drug-Conjugate, for Treatment of Acute Myeloid Leukemia $6,863,755
Cellular Biomedicine Group, Inc. Jack J. Wang Late Stage Preclinical Projects Allogenic human adipose-derived mesenchymal stem cells for the treatment of knee osteoarthritis $1,200,000
Stanford University Dr. Gary Steinberg Late Stage Preclinical Projects Intraparenchymal NR1 Stem Cell Therapy for Chronic Subcortical Ischemic Stroke $5,300,000
University of California, San Diego Dr. Stephanie Cherqui Late Stage Preclinical Projects Ex vivo transduced autologous human CD34+ hematopoietic stem cells for treatment of cystinosis $5,273,189
University of California, Los Angeles Dr. Sophie X Deng Late Stage Preclinical Projects Regeneration of a Normal Corneal Surface by Limbal Stem Cell Therapy $4,244,211
ViaCyte, Inc. Dr. Tim Kieffer Late Stage Preclinical Projects Stem cell-derived islet cell replacement therapy with immunosuppression for high-risk type 1 diabetes $3,544,721
University of California, San Francisco Dr Jennifer M Puck Late Stage Preclinical Projects Ex Vivo Transduction of the Human Artemis (DCLRE1C) cDNA by Lentiviral Vector AProArt into CD34+ Hematopoietic Cells for Artemis (ART)-Deficient Severe Combined Immunodeficiency (SCID) $4,268,865
Angiocrine Bioscience, Inc. Dr. Paul W Finnegan Late Stage Preclinical Projects Development of AB-110: genetically-modified endothelial cells plus expanded cord blood hematopoietic stem cells as a transplantation therapy $3,797,117
Calibr Peter G Schultz Late Stage Preclinical Projects Development of a Chondrogenic Drug Candidate Targeting Resident Mesenchymal Stem Cells for the Treatment of Osteoarthritis $1,667,832
Cedars-Sinai Medical Center Shaomei Wang Late Stage Preclinical Projects IND-enabling study of subretinal delivery of human neural progenitor cells for the treatment of retinitis pigmentosa $4,954,514
Calibr Peter G Schultz Preclinical Development Awards Development of a Chondrogenic Drug Candidate Targeting Cartilage-residing Mesenchymal Stem Cells for the Treatment of Osteoarthritis $2,306,703
Scripps Health Dr. Darryl D. D’Lima Preclinical Development Awards Embryonic Stem Cell-Derived Chondroprogenitor Cells to Repair Osteochondral Defects $7,660,211
University of California, Davis Dr. Roslyn Rivkah Isseroff Preclinical Development Awards Scaffold for dermal regeneration containing pre-conditioned mesenchymal stem cells to heal chronic diabetic wounds $4,620,144
University of California, Irvine Dr. Leslie M Thompson Preclinical Development Awards A hNSC Development Candidate for Huntington’s Disease $4,951,623
Stanford University Dr. Matthew H Porteus Preclinical Development Awards Pre-clinical development of gene correction therapy of hematopoietic stem cells for SCID-X1 $874,877
University of California, Davis Dr. Diana L. Farmer Preclinical Development Awards Placental Stem Cells for the In Utero Treatment of Spina Bifida $2,182,146
Salk Institute for Biological Studies Dr. David R Schubert Preclinical Development Awards Human Stem-Cell Based Development of a Potent Alzheimer’s Drug Candidate $1,664,885
ViaCyte, Inc. Howard Foyt Accelerated Development Pathway I Clinical Development of a Cell Therapy for Diabetes $8,783,852
University of California, San Diego Catriona Jamieson Alpha Stem Cell Clinics Alpha Stem Cell Clinic for the Development of Regenerative Therapies $8,679,137
University of California, Los Angeles John S. Adams Alpha Stem Cell Clinics UCLA-UCI Alpha Stem Cell Clinic (ASCC) Consortium $8,680,000
City of Hope, Beckman Research Institute Prof. John A Zaia Alpha Stem Cell Clinics The Innovation-Alpha Clinic for Cellular Therapies (I-ACT) – A Program for the Development and Delivery of Innovative Cell-based Treatments and Cures for Life-threatening Diseases. $8,416,531
University of California, Davis Dr. J. Kent Leach Tools and Technologies III Multi-modal technology for non-destructive characterization of bioengineered tissues $1,574,151
University of Southern California Dr. Qilong Ying Tools and Technologies III Embryonic stem cell-based generation of rat models for assessing human cellular therapies $1,326,979
Stanford University Sarah Heilshorn Tools and Technologies III Injectable Hydrogels for the Delivery, Maturation, and Engraftment of Clinically Relevant Numbers of Human Induced Pluripotent Stem Cell-Derived Neural Progenitors to the Central Nervous System $1,347,767
Stanford University Dr. James C. Dunn Dr. Tools and Technologies III Skin-derived precursor cells for the treatment of enteric neuromuscular dysfunction $772,098
University of California, Los Angeles Dr. James C. Dunn Dr. Tools and Technologies III Skin-derived precursor cells for the treatment of enteric neuromuscular dysfunction $1,044,423